It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Overcoming cellular growth restriction, including the evasion of cellular senescence, is a hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer subtypes and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression promotes spontaneous mammary cancer, while PAK4 gene depletion delays MMTV-PyMT driven tumors. Importantly, PAK4 prevents senescence-like growth arrest in breast cancer cells in vitro, in vivo and ex vivo, but is not needed in non-immortalized cells, while PAK4 overexpression in untransformed human mammary epithelial cells abrogates H-RAS-V12-induced senescence. Mechanistically, a PAK4 – RELB - C/EBPβ axis controls the senescence-like growth arrest and a PAK4 phosphorylation residue (RELB-Ser151) is critical for RELB-DNA interaction, transcriptional activity and expression of the senescence regulator C/EBPβ. These findings establish PAK4 as a promoter of breast cancer that can overcome oncogene-induced senescence and reveal a selective vulnerability of cancer to PAK4 inhibition.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
2 Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden; Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, P.R. China
3 Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
4 Department of Genetics, Biology and Biochemistry, University of Torino, Torino, Italy
5 Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
6 Beatson Institute for Cancer Research, Bearsden, Glasgow, UK
7 Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden
8 Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden
9 Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden
10 Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden; Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden
11 Beatson Institute for Cancer Research, Bearsden, Glasgow, UK; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA